Click Here to
News, Updates,
& More
Stay Up
to Date

A New Drug Therapy for HER2+ Breast Cancer May Be on the Horizon

Patients with HER2-positive breast cancer who develop resistance to trastuzumab may soon have an alternative therapy, according to recent findings published in Clinical Cancer Research.

This therapy involves HER2-Affitoxin, a protein that combines HER2-specific affibody molecules and a modified bacterial toxin, PE38, said Jacek Capala, PhD, DSc, an investigator at the National Cancer Institute and study investigator. Instead of interfering with the HER2 signaling pathway, as trastuzumab does, this protein uses HER2 as a means to supply a form of bacterial toxin specifically to the HER2-positive cancer cells. Upon absorption of the toxin, the cells’ production of protein is inhibited and the cells are destroyed.

Although trastuzumab may have transformed the treatment of patients with HER2-positive breast cancer, medical professionals are finding a substantial number of tumors become resistant. As a member of the medical field, have you found this to be true? Do you feel Affitoxin could potentially be an alternative treatment for HER2-positive breast cancer? Please share your thoughts, opinions, and/or experiences in the comments section below.

Related Items
Oral Toxicities Associated with Cancer Therapies: What's Old Is New Again
Meg Barbor, MPH
Web Exclusives published on November 26, 2018 in Drug Therapies
Current Treatment Options for the Management of Glioblastoma Multiforme
Larry W. Buie, PharmD, BCPS, BCOP, John M. Valgus, PharmD, BCOP, CPP
JHOP - June 2012, Vol 2, No 2 published on July 6, 2012 in Drug Therapies
The Evolution of Tyrosine Kinase Inhibitor Therapy: Improving Outcomes in Patients with Newly Diagnosed Chronic Myelogenous Leukemia
Natalie J. Greisl, PharmD, Christopher A. Fausel, PharmD, BCPS, BCOP
JHOP - December 2011 VOL 1, NO 4 published on January 6, 2012 in Drug Therapies
Current Practice in the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults
Lisa K. Lohr, PharmD, BCOP, BCPS
JHOP - December 2011 VOL 1, NO 4 published on January 5, 2012 in Drug Therapies
Postmenopausal Hormone Therapy Reduces Risk for Some Cancers
TOP - Daily published on June 15, 2011 in Drug Therapies
Hsp90 Inhibition Counters JAK/STAT-Signaling Diseases
TOP - Daily published on June 1, 2011 in Drug Therapies
Noninvasive Imaging Predicts Trastuzumab-Mediated Cardiomyopathy
TON - Daily published on May 31, 2011 in Drug Therapies
Preoperative Anti-HER2 Agents Yield Benefits
Caroline Helwick
Web Exclusives published on December 23, 2010 in Drug Therapies, In the News
Last modified: April 27, 2020